2/2- Randomized comparison of the Outcomes of single vs Multiple Arterial grafts trial in Women (ROMA:Women)
- Institution
- Icahn School of Medicine at Mount Sinai, NY
- Principal investigator
- Emilia Bagiella
- Funding
- $771K
- Duration
- 2025–2030
Moonbase score
Still being scored
Abstract
Project Summary / Abstract Coronary artery bypass grafting (CABG) is the most common adult cardiac surgery procedure, and the standard of care for patients with severe coronary artery disease. CABG can be performed using either arterial or venous grafts, with arterial grafts being associated with better outcomes in observational studies, but not in the only published randomized trial. Women represent a minority of patients in CABG trials, and there are important biological and surgical differences between men and women undergoing CABG ROMA:Women is the first trial comparing arterial vs. venous graft in a exclusive women population. In a rigorous randomized trial that focus enrollment exclusively in women we will determine 1) the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing CABG and 2) the impact of MAG vs SAG on generic and disease- specific quality of life (QOL) as well as physical and mental health symptoms in women undergoing CABG. We will enroll 2,000 women randomized 1:1 to MAG or SAG. ROMA:Women will leverage the existing infrastructure of ROMA (conducted on both Women and Men) including the clinical trial database, case report forms, randomization system, site training resources, regulatory approvals, network of participating sites, and study coordinators. The trial primary outcome will be a composite of death, stroke, non-procedural myocardial infarction, repeat revascularization and hospital readmission for acute coronary syndrome or heart failure at a minimum follow-up of 2.5 years. The secondary outcome will be the absolute changes in the Seattle Angina Questionnaire (SAQ) at 12 months compared to baseline. The trial is designed to have >90% power to demonstrate a 25% relative risk reduction in the primary composite outcome in the MAG group. Generic QOL (SF-12, EQ-5D), and symptoms (PROMIS-29) as well as key clinical events will also be captured.
Research team
- Emilia BagiellaPI
- Anne Christine GelijnsPI
LOADING MOONBASE SCORE
Questions for Icahn School of Medicine at Mount Sinai
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Icahn School of Medicine at Mount Sinai58
Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination
Joshua D Brody · $352K · 2024–2026
- NIH · Icahn School of Medicine at Mount Sinai58
Defining and targeting the lung cancer progenitor cell niche using a high-resolution, multi-omics approach
Daniel Charytonowicz · $55K · 2021–2026
- NIH · Icahn School of Medicine at Mount Sinai48
The Use of Rhythmic Light Therapy to Entrain Gamma Oscillations and the Circadian System in Patients with Alzheimer's Disease and Related Dementias (ADRD)
Mariana Gross Figueiro · $782K · 2021–2027